management of testicular cancer hassan g. taan urology resident aubmc moderator: prof. rami nasr
TRANSCRIPT
![Page 1: Management of Testicular Cancer Hassan G. TAAN Urology Resident AUBMC Moderator: Prof. Rami Nasr](https://reader035.vdocuments.site/reader035/viewer/2022062322/56649d705503460f94a5280a/html5/thumbnails/1.jpg)
Management of Testicular Cancer
Hassan G. TAANUrology Resident
AUBMC Moderator: Prof. Rami Nasr
![Page 2: Management of Testicular Cancer Hassan G. TAAN Urology Resident AUBMC Moderator: Prof. Rami Nasr](https://reader035.vdocuments.site/reader035/viewer/2022062322/56649d705503460f94a5280a/html5/thumbnails/2.jpg)
• Testicular cancer :1% male neoplasms , 5% urological tumours, incidence 3-10 /100,000 per year in West
• Risk factors : cryptorchidism, Klinefelter’s syndrome, family history, contralateral tumor, and infertility
• Germ cell tumors constitutes 95% of testicular tumors
• Testicular tumours show excellent cure rates. – proper staging– chemotherapeutic combinations– early treatment-based radiotherapy and surgery– strict follow-up & salvage therapies
![Page 3: Management of Testicular Cancer Hassan G. TAAN Urology Resident AUBMC Moderator: Prof. Rami Nasr](https://reader035.vdocuments.site/reader035/viewer/2022062322/56649d705503460f94a5280a/html5/thumbnails/3.jpg)
STAGING Of TESTICULAR CANCER
![Page 4: Management of Testicular Cancer Hassan G. TAAN Urology Resident AUBMC Moderator: Prof. Rami Nasr](https://reader035.vdocuments.site/reader035/viewer/2022062322/56649d705503460f94a5280a/html5/thumbnails/4.jpg)
Staging – AJCC (American Joint Comittee on Cancer)
• Stage 0 – CIS
• Stage I – T1-4/N0/M0– IA – T1– IB – T2-4– IS – ANY T, S1-3
• Stage II – T1-4/N1-3/M0– IIA – N1– IIB – N2– IIC – N3
• Stage III – T1-4/N1-3/M1
![Page 5: Management of Testicular Cancer Hassan G. TAAN Urology Resident AUBMC Moderator: Prof. Rami Nasr](https://reader035.vdocuments.site/reader035/viewer/2022062322/56649d705503460f94a5280a/html5/thumbnails/5.jpg)
Tumour Markers• Alpha-fetoprotein– Trophoblasts– Major serum binding protein produced by foetal yolk sac, liver, GIT– Negligible amounts after 1 year of age– T1/2 :4-6 days
• Beta-human chorionic gonadotrophin– Syncytiotrophoblasts– Secreted by placenta for maintanence of corpus luteum– T1/2:24 hours
• LDH– tumour burden
![Page 6: Management of Testicular Cancer Hassan G. TAAN Urology Resident AUBMC Moderator: Prof. Rami Nasr](https://reader035.vdocuments.site/reader035/viewer/2022062322/56649d705503460f94a5280a/html5/thumbnails/6.jpg)
![Page 7: Management of Testicular Cancer Hassan G. TAAN Urology Resident AUBMC Moderator: Prof. Rami Nasr](https://reader035.vdocuments.site/reader035/viewer/2022062322/56649d705503460f94a5280a/html5/thumbnails/7.jpg)
GERM CELL TUMORS• Seminoma :
– Typical/Classic (82 – 85 % of seminomas)
– Spermatocytic (2 – 12 % of seminomas)—extremely low metastatic potential. Men>50years
– Anaplastic previously classified as separate entity that was believed to be more aggressive/lethal due to greater mitotic activity. However, mitotic index is not associated with worse prognosis, so term no longer used
• Nonseminomatous Germ Cell Tumors Embryonal cell carcinoma Yolk sac tumor Teratoma Choriocarcinoma • Mixed Tumors • Intratubular germ cell neoplasia (CIS)
![Page 8: Management of Testicular Cancer Hassan G. TAAN Urology Resident AUBMC Moderator: Prof. Rami Nasr](https://reader035.vdocuments.site/reader035/viewer/2022062322/56649d705503460f94a5280a/html5/thumbnails/8.jpg)
• Frequency of Histologic causes:
GCT constitute 90 – 95% of all primary testicular malignancies
Seminoma: 30 – 60% Embryonal carcinoma: 3- 4 % in pure form (present in 40% of NSGCTs)
Teratoma: 5 – 10% Pure choriocarcinoma: 1% Mixed GCTs: 60%
![Page 9: Management of Testicular Cancer Hassan G. TAAN Urology Resident AUBMC Moderator: Prof. Rami Nasr](https://reader035.vdocuments.site/reader035/viewer/2022062322/56649d705503460f94a5280a/html5/thumbnails/9.jpg)
PATTERNS OF SPREAD OF GCTs
• Right testis : - Interaortocaval nodes at level of 2nd vertebral body • Left testis : Left paraaortic and preaortic nodes (bounded by left ureter, left renal
vein, aorta and origin of IMA)
• Cross-over: Right to left (but NOT left to right)
• Epididymis: external iliac chain
• Inguinal node mets may occur if: Scrotal involvement of primary tumor Prior inguinal or scrotal surgery Retrograde lymphatic spread from massive retroperitoneal LN deposits
![Page 10: Management of Testicular Cancer Hassan G. TAAN Urology Resident AUBMC Moderator: Prof. Rami Nasr](https://reader035.vdocuments.site/reader035/viewer/2022062322/56649d705503460f94a5280a/html5/thumbnails/10.jpg)
![Page 11: Management of Testicular Cancer Hassan G. TAAN Urology Resident AUBMC Moderator: Prof. Rami Nasr](https://reader035.vdocuments.site/reader035/viewer/2022062322/56649d705503460f94a5280a/html5/thumbnails/11.jpg)
STAGE I SEMINOMA
• The overall CSS rate under surveillance : 97-100% for seminoma stage I .
• The drawback of surveillance :intensive follow-up, repeated imaging of the retroperitoneal lymph nodes, for at least 5 years after orchidectomy
• There was no significant difference between one cycle of carboplatin compared to adjuvant radiotherapy, with regard to recurrence rate, time to recurrence, and survival after a median follow-up of 4 years
• Adjuvant radiotherapy to a para-aortic field or to a hockeystick field , with moderate doses (total 20-24 Gy), will reduce the relapse rate to 1-3%
![Page 12: Management of Testicular Cancer Hassan G. TAAN Urology Resident AUBMC Moderator: Prof. Rami Nasr](https://reader035.vdocuments.site/reader035/viewer/2022062322/56649d705503460f94a5280a/html5/thumbnails/12.jpg)
SURVEILLANCE FOR STAGE I SEMINOMA
• H& PE ,serum tumor markers (bhCG, LDH, AFP) every 3-4 months the first year, every 6 months the second year, then annually thereafter
• Imaging: Chest radiography each visit; CT scan of the pelvis annually for 3 years if status post para-aortic radiotherapy
![Page 13: Management of Testicular Cancer Hassan G. TAAN Urology Resident AUBMC Moderator: Prof. Rami Nasr](https://reader035.vdocuments.site/reader035/viewer/2022062322/56649d705503460f94a5280a/html5/thumbnails/13.jpg)
STAGE IIA-B SEMINOMA
• 15 to 20 percent of seminoma patients have CS II disease, 70% of whom have CS IIA-B. Dog-leg radiotherapy using 25 to 30 Gy is employed at most centers
• Long-term disease-free survival rates are 92% to 100% for CS IIA and 87% to 90% for CS IIB , with in-field recurrences reported in 0% to 2% and 0% to 7% of cases, respectively
• Relapses are cured in virtually all cases with first-line chemotherapy, and disease-specific survival approaches 100%
• Induction chemotherapy using first-line regimens (BEP×3 or EP×4) is an accepted alternative to dog-leg radiotherapy for patients with bulky (>3 cm) and/or multiple retroperitoneal masses because the risk of relapse is lower than with dog-leg radiotherapy (15% and 30% of CS IIA and IIB patients in one center)
![Page 14: Management of Testicular Cancer Hassan G. TAAN Urology Resident AUBMC Moderator: Prof. Rami Nasr](https://reader035.vdocuments.site/reader035/viewer/2022062322/56649d705503460f94a5280a/html5/thumbnails/14.jpg)
Surveillance for stage IIa/b seminoma
• H& PE and serum tumor markers every 3-4 months in years 1-3, every 6 months in year 4, and then annually thereafter
• Imaging: Radiography each visit; CT scan of the abdomen and pelvis during month 4 of the first year
![Page 15: Management of Testicular Cancer Hassan G. TAAN Urology Resident AUBMC Moderator: Prof. Rami Nasr](https://reader035.vdocuments.site/reader035/viewer/2022062322/56649d705503460f94a5280a/html5/thumbnails/15.jpg)
![Page 16: Management of Testicular Cancer Hassan G. TAAN Urology Resident AUBMC Moderator: Prof. Rami Nasr](https://reader035.vdocuments.site/reader035/viewer/2022062322/56649d705503460f94a5280a/html5/thumbnails/16.jpg)
STAGE IIC AND III
• Patients with CS IIC and III seminoma are treated with induction chemotherapy
• Ninety percent of patients with advanced seminoma are classified as good risk and should receive either BEP×3 or EP×4 chemotherapy
• Complete radiographic responses are reported in 70% to 90% of patients, and the 5-year overall survival is 91%
• With BEP×4 chemotherapy, the 5-year overall and progression-free survival is 79% and 75%, respectively
![Page 17: Management of Testicular Cancer Hassan G. TAAN Urology Resident AUBMC Moderator: Prof. Rami Nasr](https://reader035.vdocuments.site/reader035/viewer/2022062322/56649d705503460f94a5280a/html5/thumbnails/17.jpg)
Surveillance for stage IIc, III seminoma
• H& PE and serum tumor markers every 2 months the first year, every 3 months the second year, every 4 months the third year, every 6 months the fourth year, and then annually thereafter
• Imaging: Chest radiography each visit; CT scan of the abdomen and pelvis during month 4 of the first year status post surgery (otherwise, every 3 months until stable); PET scan as clinically indicated
![Page 18: Management of Testicular Cancer Hassan G. TAAN Urology Resident AUBMC Moderator: Prof. Rami Nasr](https://reader035.vdocuments.site/reader035/viewer/2022062322/56649d705503460f94a5280a/html5/thumbnails/18.jpg)
Follow Up - Seminoma
![Page 19: Management of Testicular Cancer Hassan G. TAAN Urology Resident AUBMC Moderator: Prof. Rami Nasr](https://reader035.vdocuments.site/reader035/viewer/2022062322/56649d705503460f94a5280a/html5/thumbnails/19.jpg)
Relapses
• Surveillance/Radiotherapy– BEP x 3
• Chemotherapy cohort– VIP x 4 (vinblastine, ifosfamide and cisplatin) or– TIP x 4 (paclitaxol, ifosfamide and cisplatin)
![Page 20: Management of Testicular Cancer Hassan G. TAAN Urology Resident AUBMC Moderator: Prof. Rami Nasr](https://reader035.vdocuments.site/reader035/viewer/2022062322/56649d705503460f94a5280a/html5/thumbnails/20.jpg)
Prognostic factors for occult metastatic disease in testicular cancer
![Page 21: Management of Testicular Cancer Hassan G. TAAN Urology Resident AUBMC Moderator: Prof. Rami Nasr](https://reader035.vdocuments.site/reader035/viewer/2022062322/56649d705503460f94a5280a/html5/thumbnails/21.jpg)
Impact on fertility and fertility-associated issues
• In patients in the reproductive age group, pre-treatment fertility assessment (testosterone, LH and FSH levels) should be performed, and
semen analysis and cryopreservation should be offered.
• If cryopreservation is desired, it should preferably be performed before orchidectomy, but in any case prior to chemotherapy treatment
• In cases of bilateral orchidectomy or low testosterone levels after treatment of TIN, life-long testosterone supplementation is necessary
• Patients with unilateral or bilateral orchidectomy should be offered a testicular prosthesis
![Page 22: Management of Testicular Cancer Hassan G. TAAN Urology Resident AUBMC Moderator: Prof. Rami Nasr](https://reader035.vdocuments.site/reader035/viewer/2022062322/56649d705503460f94a5280a/html5/thumbnails/22.jpg)
Non Sminoma Germ Cell Tumors
• Approximately one third of NSGCT patients have CS I with normal postorchiectomy levels of serum tumor markers
• The optimal management of these patients continues to generate controversy because the long-term survival associated with surveillance, RPLND, and primary chemotherapy approaches 100%
• Up to 30% of NSGCT patients with clinical stage I (CS1) disease have subclinical metastases and will relapse if surveillance alone is applied after orchidectomy.
![Page 23: Management of Testicular Cancer Hassan G. TAAN Urology Resident AUBMC Moderator: Prof. Rami Nasr](https://reader035.vdocuments.site/reader035/viewer/2022062322/56649d705503460f94a5280a/html5/thumbnails/23.jpg)
![Page 24: Management of Testicular Cancer Hassan G. TAAN Urology Resident AUBMC Moderator: Prof. Rami Nasr](https://reader035.vdocuments.site/reader035/viewer/2022062322/56649d705503460f94a5280a/html5/thumbnails/24.jpg)
Surveillance In NSGCT CS1
• Close surveillance after orchidectomy in CS1 NSGCT patients showed a cumulative relapse rate of ~30%, with 80% of relapses occurring during the first
12 months of follow-up, 12% during the second year and 6% during the third year, decreasing to 1% during the fourth and fifth years
• 35% of relapsing patients have normal levels of serum tumour markers at relapse. 60% of relapses are in the retroperitoneum
• Despite very close follow-up, 11% of relapsing patients presented with large-volume recurrent disease.
• surveillance within an experienced surveillance programme may be offered to patients with non-risk stratified clinical stage I non-seminoma as long as they are compliant and informed about the expected recurrence rate as well as the salvage treatment
![Page 25: Management of Testicular Cancer Hassan G. TAAN Urology Resident AUBMC Moderator: Prof. Rami Nasr](https://reader035.vdocuments.site/reader035/viewer/2022062322/56649d705503460f94a5280a/html5/thumbnails/25.jpg)
Follow Up – Surveillance Stage I NSGCT
![Page 26: Management of Testicular Cancer Hassan G. TAAN Urology Resident AUBMC Moderator: Prof. Rami Nasr](https://reader035.vdocuments.site/reader035/viewer/2022062322/56649d705503460f94a5280a/html5/thumbnails/26.jpg)
Primary chemotherapy In NSGCT CS1
• Several studies involving two courses of chemotherapy with cisplatin, etoposide and bleomycin (PEB) as primary treatment for high-risk patients (having ~50% risk of relapse) have been reported .
• In these series, involving > 200 patients, some with a median follow-up of nearly 8 years , a relapse rate of only 2.7% was reported, with very little long-term toxicity
• Two cycles of cisplatin-based adjuvant chemotherapy do not seem to adversely affect fertility or sexual activity
• slow-growing retroperitoneal teratomas after primary chemotherapy
![Page 27: Management of Testicular Cancer Hassan G. TAAN Urology Resident AUBMC Moderator: Prof. Rami Nasr](https://reader035.vdocuments.site/reader035/viewer/2022062322/56649d705503460f94a5280a/html5/thumbnails/27.jpg)
Retroperitoneal lymph node dissection
• If RPLND done, ~30% have lymph node involvement, pathological stage II (PS2) disease . RPLND -> -ve L.N (PS1), ~10% of the PS1 patients relapse at distant sites.
• The main predictor of relapse in CS1 NSGCT managed by surveillance, for having PS2 disease and for relapse in PS1 after RPLND- vascular invasion in the primary tumour .
• Patients without vascular invasion constitute ~50-70% of the CS1 population, and these patients have only a 15-20% risk of relapse on surveillance, VS 50% relapse rate in patients with vascular invasion
![Page 28: Management of Testicular Cancer Hassan G. TAAN Urology Resident AUBMC Moderator: Prof. Rami Nasr](https://reader035.vdocuments.site/reader035/viewer/2022062322/56649d705503460f94a5280a/html5/thumbnails/28.jpg)
• The risk of relapse for PS1 patients is < 10% for those without vascular invasion and ~30% for those with vascular invasion
• If two (or more) courses of cisplatin-based chemotherapy are given adjuvant to RPLND in PS2 cases, the relapse rate is reduced to < 2%, including teratoma relapse .
• The risk of retroperitoneal relapse after a properly performed nerve-sparing RPLND is very low (< 2%), as is the risk of ejaculatory disturbance or other significant side-effects
![Page 29: Management of Testicular Cancer Hassan G. TAAN Urology Resident AUBMC Moderator: Prof. Rami Nasr](https://reader035.vdocuments.site/reader035/viewer/2022062322/56649d705503460f94a5280a/html5/thumbnails/29.jpg)
• In a randomised comparison of RPLND with one course of PEB chemotherapy, adjuvant chemotherapy significantly increased the 2-year recurrence-free survival to 99.41% as opposed to surgery, which had a 2-year recurrence-free survival of 92.37%
• It was also found that one adjuvant PEB reduced the number of recurrences to 3.2% in the high-risk and to 1.4% in the low-risk patients
![Page 30: Management of Testicular Cancer Hassan G. TAAN Urology Resident AUBMC Moderator: Prof. Rami Nasr](https://reader035.vdocuments.site/reader035/viewer/2022062322/56649d705503460f94a5280a/html5/thumbnails/30.jpg)
![Page 31: Management of Testicular Cancer Hassan G. TAAN Urology Resident AUBMC Moderator: Prof. Rami Nasr](https://reader035.vdocuments.site/reader035/viewer/2022062322/56649d705503460f94a5280a/html5/thumbnails/31.jpg)
CS1S with (persistently) elevated serum tumour markers
• If the marker level increases after orchidectomy, the patient has residual disease. If RPLND is performed, up to 87% of these patients have pathological finding in the nodes .
• An U/S of the contralateral testicle must be performed, if this was not done initially.
• The treatment of true CS1S patients is still controversial. They may be treated with three courses of primary PEB chemotherapy and with follow-up as for CS1B patients (high risk) after primary chemotherapy, or by RPLND .
• The presence of vascular invasion may strengthen the indication for primary chemotherapy as most CS1S with vascular invasion will need chemotherapy
sooner or later
![Page 32: Management of Testicular Cancer Hassan G. TAAN Urology Resident AUBMC Moderator: Prof. Rami Nasr](https://reader035.vdocuments.site/reader035/viewer/2022062322/56649d705503460f94a5280a/html5/thumbnails/32.jpg)
PS – pathologic stage,PD – progressive disease, NC – no change
![Page 33: Management of Testicular Cancer Hassan G. TAAN Urology Resident AUBMC Moderator: Prof. Rami Nasr](https://reader035.vdocuments.site/reader035/viewer/2022062322/56649d705503460f94a5280a/html5/thumbnails/33.jpg)